ENZON PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1981-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.enzon.com
Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell Transplant
Phase 1
Completed
- Conditions
- Multiple Myeloma
- Interventions
- Drug: Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)
- First Posted Date
- 2006-10-17
- Last Posted Date
- 2011-12-05
- Lead Sponsor
- Enzon Pharmaceuticals, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT00388999
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
A Study Evaluating IV Oncaspar® and IV Gemzar® in the Treatment of Solid Tumors and Lymphoma
Phase 1
Terminated
- Conditions
- TumorsLymphoma
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2008-05-20
- Lead Sponsor
- Enzon Pharmaceuticals, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT00363610
- Locations
- 🇺🇸
TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale, Arizona, United States
🇺🇸Cancer Therapy & Research Center, Institute for Drug Development, San Antonio, Texas, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction
Phase 2
Terminated
- Conditions
- Cancer of StomachGastroesophageal Cancer
- First Posted Date
- 2004-03-23
- Last Posted Date
- 2012-09-06
- Lead Sponsor
- Enzon Pharmaceuticals, Inc.
- Registration Number
- NCT00080002
Efficacy and Safety Evaluation of Pegamotecan (PEG-camptothecin) in Advanced or Metastatic Soft Tissue Sarcoma
Phase 2
Suspended
- Conditions
- Sarcoma, Soft Tissue
- First Posted Date
- 2004-03-22
- Last Posted Date
- 2012-09-06
- Lead Sponsor
- Enzon Pharmaceuticals, Inc.
- Registration Number
- NCT00079950
- Locations
- 🇺🇸
Pennsylvania Oncology Hematology Association, Philadelphia, Pennsylvania, United States
🇺🇸Century City Hospital, Los Angeles, California, United States
🇺🇸University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas
Phase 1
Terminated
- Conditions
- NeoplasmLymphomasNeoplasm Metastasis
- First Posted Date
- 2001-08-27
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Enzon Pharmaceuticals, Inc.
- Registration Number
- NCT00023166
© Copyright 2025. All Rights Reserved by MedPath